9,10-Anthraquinone hinders β-aggregation: How does a small molecule interfere with Aβ-peptide amyloid fibrillation?

Protein Science

Volumn 18, Issue 4, 2009, Pages 792-800

  Convertino, Marino ^a,b   Pellarin, Riccardo ^a   Catto, Marco ^b   Carotti, Angelo ^b   Caflisch, Amedeo ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

9,10 anthraquinone; Aggregation inhibition; Alzheimer's disease; Amyloid; Implicit solvent; Molecular dynamics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; ANTHRACENE; ANTHRAQUINONE; OLIGOMER; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; HYDROGEN BOND; MOLECULAR DYNAMICS; NERVE DEGENERATION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION;

AMYLOID; AMYLOID BETA-PROTEIN; ANTHRACENES; ANTHRAQUINONES; COMPUTER SIMULATION; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 63449131863     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.87     Document Type: Article

References (55)

1. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774-779.
2. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid P-peptide. Nat Rev Mol Cell Biol 8:101-112.
3. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426:905-909.
4. Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282:10311-10324.
5. Kokkoni N, Stott K. Amijee H, Mason JM, Doig AJ (2006) N-methylated peptide inhibitors of β-amyloid aggregation and toxicity, optimization of the inhibitor structure. Biochemistry 45:9906-9918.
6. Yan L-M, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A (2007) IAPP mimic blocks Aβ cytotoxic self-assembly: cross-suppression of amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl 46:1246-1252.
7. Ban T, Hoshino M, Takahashi S, Hamada D, Hasegawa K, Naiki H, Goto Y (2004) Direct observation of Aβ amyloid fibril growth and inhibition. J Mol Biol 344: 757-767.
8. Kanapathipillai M, Lentzen G, Sierks M, Park CB (2005) Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's β-amyloid. FEBS Lett 579: 4775-4780.
9. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M. Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P (2007) Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28:537-547.
10. Mishra R, Bulic B, Sellin D, Jha S, Waldmann H, Winter R (2008) Small-molecule inhibitors of islet amyloid polypeptide fibril formation. Angew Chem Int Ed Engl 47: 4679-4682.
11. Porat Y, Mazor Y, Efrat S, Gazit E (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43:14454-14462.
12. Cohen T, Frydman-Marom A, Rechter M, Gazit E (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45:4727-4735.
13. Morshedi D, Rezaei-Ghaleh N, Ebrahim-Habibi A, Ahmadian S Nemat-Gorgani M (2007) Inhibition of amyloid fibrillation of lysozyme by indole derivatives-possible mechanism of action. FEBS J 274:6415-6425.
14. Tomiyama T, Kaneko H, Kataoka K, Asano S, Endo N (1997) Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 322 (Part 3): 859-865.
15. Lieu VH, Wu JW, Wang SS-S, Wu C-H (2007) Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol Prog 23: 698-706.
16. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y. Hascher A, Mandelkow E-M, Biernat J, Mandelkow E (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 280:3628-3635.
17. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SSN, Mount HTJ, Fraser PE, Westaway D, George-Hyslop PS (2006) Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801-808.
18. Ma B, Nussinov R (2002) Stabilities and conformations of Alzheimer's β-amyloid peptide oligomers (Aβ 16-22, Aβ 16-35, and Aβ 10-35): sequence effects. Proc Natl Acad Sci USA 99:14126-14131.
19. Gsponer J, Haberthtir U, Caflisch A (2003) The role of side-chain interactions in the early steps of aggregation: Molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc Natl Acad Sci USA 100:5154-5159.
20. Klimov DK, Thirumalai D (2003) Dissecting the assembly of Aβ16-22 amyloid peptides into antiparallel β sheets. Structure 11:295-307.
21. Hwang W, Zhang S, Kamm RD, Karplus M (2004) Kinetic control of dimer structure formation in amyloid fibrillogenesis. Proc Natl Acad Sci USA 101:12916-12921.
22. Buchete N-V, Tycko R, Hummer G (2005) Molecular dynamics simulations of Alzheimer's β-amyloid protofilaments. J Mol Biol 353:804-821.
23. de la Paz ML, de Mori GMS, Serrano L, Colombo G (2005) Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol 349:583-596.
24. Melquiond A, Mousseau N, Derreumaux P (2006) Structures of soluble amyloid oligomers from computer simulations. Proteins 65:180-191.
25. Cecchini M, Rao F, Seeber M, Caflisch A (2004) Replica exchange molecular dynamics simulations of amyloid peptide aggregation. J Chem Phys 121:10748-10756.
26. Cheon M, Chang I, Mohanty S, Luheshi LM, Dobson CM, Vendruscolo M, Favrin G (2007) Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol 3:1727-1738.
27. Hills RD, Brooks CL (2007) Hydrophobic cooperativity as a mechanism for amyloid nucleation. J Mol Biol 368: 894-901.
28. Simone AD, Esposito L, Pedone C, Vitagliano L (2008) Insights into stability and toxicity of amyloid-like oligomers by replica exchange molecular dynamics analyses. Biophys J 95:1965-1973.
29. Cecchini M, Curcio R. Pappalardo M, Melki R. Caflisch A (2006) A molecular dynamics approach to the structural characterization of amyloid aggregation. J Mol Biol 357: 1306-1321.
30. Soto P, Griffin MA, Shea J-E (2007) New insights into the mechanism of Alzheimer amyloid-beta fibrillogenesis inhibition by N-methylated peptides. Biophys J 93: 3015-3025.
31. Frydman-Marom A, Rechter M, Bram V. Shalev DE, Gazit E (2009) Cognitive performance recovery of Alzheimer's disease model mice by modulating early soluble amyloidal assemblies. Angew Chem Int Ed Engl 48:1981-1986.
32. Tjernberg LO, Näslund J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271:8545-8548.
33. Williams AD, Portelius E, Kheterpal I, Tao Guo J, Cook KD, Xu Y, Wetzel R (2004) Mapping Aβ amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol 335:833-842.
34. Caflisch A (2006) Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol 10:437-444.
35. Tartaglia GG, Cavalli A, Pellarin R. Caflisch A (2005) Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 14:2723-2734.
36. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent anti-amyloidogenic affects for Alzheimer's β-amyloid fibrils in vitro. J Neurosci Res 75:742-750.
37. Bartolini M. Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V (2007) Insight into the kinetic of Amyloid B (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chem Biol Chem 8: 2152-2161.
38. Meng F, Marek P, Potter KJ, Verchere CB, Raleigh DP (2008) Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril Thioflavin-T interactions: implications for mechanistic studies of β-cell death. Biochemistry 47:6016-6024.
39. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217.
40. Ferrara P, Apostolakis J, Caflisch A (2002) Evaluation of a fast implicit solvent model for molecular dynamics simulations. Proteins: Struct Funct Bioinformat 46:24-33.
41. No K, Grant J, Scheraga H (1990) Determination of net atomic charges using a modified partial equalization of orbital electronegativity method. 1. Application to neutral molecules as models for polypeptides. J Phys Chem 94: 4732-4739.
42. No K. Grant J, Jhon M. Scheraga H (1990) Determination of net atomic charges using a modified partial equalization of orbital electronegativity method. 2. Application to ionic and aromatic molecules as models for polypeptides. J Phys Chem 94:4740-4746.
43. Li Y, Snyder L, Langley DR (2003) Electrostatic interaction of π-acidic amides with hydrogen-bond acceptors. Bioorganic & Medicinal Chemistry Letters 13:3261-3266.
44. Fu Y, Brock CP (1998) Temperature dependence of the rigid-body motion of Anthraquinone. Acta Cryst B 54: 308-315.
45. LeVine H, III. 1993. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein 2:404-410.
46. Meyer EA, Castellano RK. Diederieh F (2003) Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl 42:1210-1250.
47. Thalladi VR, Katz AK, Carrell HL, Nangia A, Desiraju GR (1998) Trimethyl isocyanurate and triethyl isocyannrate. Acta Crystallogr C 54 (Part 1):86-89.
48. Frontera A, Saczewski F, Gdaniec M, Dziemidowicz-Borys E, Kurland A, Deyà PM, Quiñonero D, Garau C (2005) Anion-π interactions in cyanuric acids: a combined crystallographic and computational study. Chemistry 11: 6560-6567.
49. Garau C, Frontera A, Quinonero D, Ballester P, Costa A, Deya PM. (2004) Cation-π versus anion-π interactions: a comparative ab initio study based on energetic, electron charge density and aromatic features. Chem Phys Lett 392:85-89.
50. Pellarin R, Caflisch A (2006) Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol 360:882-892.
51. Pellarin R, Guarnera E, Caflisch A (2007) Pathways and intermediates of amyloid fibril formation. J Mol Biol 374: 917-924.
52. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepard-son HE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842.
53. Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM (2008) Amyloid-β dynamics correlate with neurological status in the injured human brain. Science 321: 1221-1224.
54. Bandiera T, Lansen J, Post C, Varasi M (1997) Inhibitors of Aβ peptide aggregation as potential anti-Alzheimer agents. Curr Med Chem 4:159-170.
55. Colombo R, Carotti A, Catto M, Racchi M, Lanni C, Verga L, Gabriele C, De Lorenzi E (in press) Capillary electrophoresis can identify small molecules that selectively target soluble oligomers of Aβ protein and display antifibrillogenic activity. Electrophoresis.